InnoCare has received CDE/NMPA clearance to initiate a Phase II/III study of its oral TYK2 inhibitor soficitinib (ICP-332) in chronic spontaneous urticaria (CSU). No efficacy or safety data were disclosed; the authorization enables a registration-oriented path in China.
The core move is an IND approval for a seamless mid-to-late stage program in CSU, extending InnoCare’s TYK2 franchise beyond atopic dermatitis and vitiligo into a high-prevalence, biologics-active market. A Phase II/III structure in China typically signals an adaptive or seamless design intended to compress timelines between signal detection and confirmatory evaluation. For CSU, trials usually enroll antihistamine-refractory patients and hinge on changes in validated urticaria scores over 12–24 weeks, often as add-on therapy.
Strategically, this is a calculated expansion into immunodermatology where small-molecule selectivity claims around TYK2 are being tested against entrenched biologics and emerging BTK inhibitors. With omalizumab already embedded in care algorithms and dupilumab gaining traction in antihistamine-inadequate responders, any oral entrant must demonstrate not just symptom reduction but operational advantages in access, monitoring, and persistence. The choice of TYK2 positions InnoCare away from broader JAK exposure that has drawn regulatory caution, while aiming to intercept upstream cytokine signaling relevant to itch and wheal formation. The Phase II/III designation also reflects urgency: Novartis has advanced remibrutinib in CSU with positive Phase 3 data and regulatory filings in motion, and timelines will matter if InnoCare intends to compete for second-line share.
For sites and CROs, CSU offers scale but demands disciplined execution. Patient-reported outcomes and daily symptom diaries (e.g., UAS7) drive endpoints, making ePRO adherence and nighttime symptom capture pivotal. Dermatology and allergy clinics in China can recruit at volume. Still, the pool is under active solicitation from biologic and small-molecule programs, so startup speed, site payments, and digital tools for diary compliance will be differentiators. Safety oversight will focus on infection signals and lab trends common to the JAK/TYK2 class, though a selective TYK2 profile could ease monitoring complexity compared with pan-JAKs. Vendors supporting remote data capture, algorithmic adherence nudges, and multilingual patient support could materially improve data completeness on itch and wheal trajectories.
For sponsors and regulators, the study’s control strategy will be telling. A placebo add-on to H1 antihistamines is operationally simple but may struggle against rising ethical expectations when biologic standards are in place; active-comparator arms against omalizumab or stratification by prior biologic exposure would better position a filing but would also expand sample size and cost. CDE has supported seamless designs, but consistency across subgroups and durability beyond 24 weeks will be critical for a chronic indication. Any intent to bridge outside China will require alignment on endpoint hierarchies and background therapy rules consistent with FDA and EMA expectations.
What to watch next: protocol specifics, including background antihistamine stabilization, prior biologic exposure caps, and whether the Phase II/III is formally adaptive. Early safety run-in data will be scrutinized, given the class landscape, and any biomarker strategy to segment responders could de-risk a head-to-head path. Commercially, InnoCare will need to outline dermatology-focused field capabilities and potential partnerships if the program advances quickly. The open question is whether a selective TYK2 inhibitor can carve out a CSU position against biologics and BTKs on the strength of oral convenience and acceptable safety, or whether the bar has already moved to mechanism-specific head-to-head evidence.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
